Sarclisa (isatuximab-irfc) / ImmunoGen, AbbVie, Sanofi  >>  Phase 1
Welcome,         Profile    Billing    Logout  

15 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sarclisa (isatuximab-irfc) / Sanofi
NCT02283775: SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

Hourglass Jan 2021 - Dec 2021 : From pomdeSAR trial in combination with pomalidomide and dexamethasone for r/r multiple myeloma
Checkmark First data from pomalidomide and dexamthasone combination trial at ASH 2019
Nov 2019 - Nov 2019: First data from pomalidomide and dexamthasone combination trial at ASH 2019
Checkmark P1b PomdeSAR trial at ASH 2017 [screen shot]
Dec 2017 - Dec 2017: P1b PomdeSAR trial at ASH 2017 [screen shot]
Completed
1b
54
US
Isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone
Sanofi
Plasma Cell Myeloma
05/21
05/21
NCT01749969: SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Hourglass Jul 2020 - Dec 2020 : From P1b trial for r/r multiple myeloma
Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
More
Completed
1b
57
US
isatuximab SAR650984, Sarclisa, lenalidomide, Revlimid, dexamethasone
Sanofi
Plasma Cell Myeloma
06/23
06/23
NCT03733717: Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Hourglass Jan 2020 - Dec 2020 : First data from P1 trial in Chinese patients with r/r multiple myeloma
Completed
1
25
RoW
Isatuximab SAR650984, Sarclisa
Sanofi
Multiple Myeloma
09/20
08/23
NCT02514668: A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Checkmark From trial in multiple myeloma
Nov 2020 - Nov 2020: From trial in multiple myeloma
Completed
1
55
Europe, US, RoW
Isatuximab, SAR650984, Sarclisa
Sanofi
Plasma Cell Myeloma
12/21
12/21
CyBorDSAR, NCT02513186: Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Hourglass Jan 2023 - Dec 2023 : From trial in combination with bortezomib for multiple myeloma
Completed
1
90
Europe
lenalidomide, Revlimid, bortezomib, Velcade, cyclophosphamide, Endoxan, dexamethasone, isatuximab SAR650984, Sarclisa
Sanofi
Plasma Cell Myeloma
01/22
01/24
NCT04912427: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Terminated
1
1
US
Isatuximab, Sarclisa, Bortezomib, Velcade, Dexamethasone
Washington University School of Medicine, Sanofi
Multiple Myeloma
12/22
01/24
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Hourglass Apr 2020 - Jun 2020 : From trial in combination with bendamustine for penta-refractory multiple myeloma
Terminated
1
15
US
Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol
Washington University School of Medicine, Sanofi
Multiple Myeloma
03/23
03/24
NCT04045795: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Completed
1
56
Europe, Japan, US, RoW
isatuximab SAR650984 IV, Sarclisa, pomalidomide, Pomalyst®, dexamethasone, Decadron®, isatuximab SAR650984 SC, Investigational injector device
Sanofi
Multiple Myeloma
03/24
03/24
NCI-2023-09969, NCT06203912: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
3
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Echocardiography, EC, Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR-650984, SAR650984, Sarclisa, Questionnaire Administration, Universal Donor Expanded TGF-beta-imprinted NK Cells, Allogeneic TGFBi Expanded NK Cells, UD TGF-betai NK Cells, Universal Donor TGF-beta Imprinted Expanded NK Cells
Elvira Umyarova, Sanofi
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
01/26
01/26
TTI-622-01, NCT03530683: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Checkmark First patient dosed in combination with azacitidine for TP53-mutated AML
Aug 2021 - Aug 2021: First patient dosed in combination with azacitidine for TP53-mutated AML
Checkmark Data from trial for lymphoma
Apr 2021 - Apr 2021: Data from trial for lymphoma
Terminated
1
189
US
Maplirpacept (PF-07901801), SIRPα-IgG4 Fc, TTI-622, Azacitidine, VIDAZA, Venetoclax, VENCLEXTA, Carfilzomib, KYPROLIS, Dexamethasone, Anti-CD20 Targeting agent, Ruxience or Rituxan, Isatuximab, Sarclisa
Pfizer
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
07/24
07/24
NCT02332850: Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
83
Canada, US
Isatuximab, SAR 650984, Carfilzomib, Kyprolis, PR-171, Dexamethasone, Orgadrone, Spersadex, Visumetazone
Thomas Martin, MD, Amgen, Sanofi
Multiple Myeloma
12/25
12/25
NCT05284032: A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

Terminated
1
3
US
isatuximab 10 mg/kg
Firas El Chaer, MD
Platelet Refractoriness, Hematologic Malignancy
06/24
06/24
NCT05862766: Isatuximab in Lung Transplant Recipients

Withdrawn
1
6
US
Isatuximab, SARCLISA®, bone marrow biopsy
NYU Langone Health
Antibody-mediated Rejection, Allosensitization
01/26
01/27
NCT04754945: Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Active, not recruiting
1
11
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa
Emory University, Sanofi, National Cancer Institute (NCI)
AL Amyloidosis
07/25
07/26
LINKER-MM2, NCT05137054: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Recruiting
1
317
Europe, US, RoW
Linvoseltamab, REGN5458, Lynozyfic™, Daratumumab, Darzalex®; Darzalex Faspro™, Carfilzomib, Kyprolis®, Lenalidomide, Revlimid®, Bortezomib, Velcade®, Pomalidomide, Imnovid, Pomalyst®, Isatuximab, Sarclisa®, Fianlimab, REGN3767, Cemiplimab, LIBTAYO, REGN2810, Nirogacestat, PF-03084014, Cevostamab, BFCR4350A, RO7187797
Regeneron Pharmaceuticals
Multiple Myeloma
04/28
09/34

Download Options